Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Hyloris Pharmaceuticals SA

News headline image
Hyloris to Report 2023 Full-Year Results on 14 March 2024
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris announces US FDA approval for Podofilox Gel
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris announces U.S. FDA Approval of Maxigesic® IV
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris shareholders approve all resolutions at the Annual General Meeting
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris announces potential registration date for Maxigesic® IV in the US
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris releases Annual Report 2022, including ESG objectives
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris reports full year results for 2022 & provides business outlook
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Announces Commercial Partnership for Maxigesic® IV in 9 European Countries
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia)
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
News headline image
Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its Employees
From Hyloris Pharmaceuticals SA
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.